Background & aims: Very few data are available in literature about the role of radiofrequency ablation (RFA) in intrahepatic cholangiocarcinoma (ICC) and previous studies are mainly case reports and case series on a very small number of patients and nodules. In this study, we aimed to evaluate effectiveness and safety of RFA for the treatment of unresectable ICC. Methods: This is a retrospective observational cohort study comprising all consecutive patients treated with RFA for unresectable ICC at Policlinico Sant’Orsola Malpighi Hospital, Bologna, Italy. Primary endpoint was Local Tumor Progression-Free Survival (LTPFS) while Overall Survival (OS) was also assessed as secondary endpoint. Results: From January 2014 to June 2019, 29 patients with 117 nodules underwent RFA. Technique effectiveness 1 month after RFA was 92.3%; median LTPFS was 9.27 months. Univariate analysis and multivariate analysis showed that LTPFS was significantly related to tumor size ≥20 mm. At a median follow up of 39.9 months, median OS from the date of RFA was 27.5 months, with an OS of 89%, 45% and 11% at 1, 2 and 4 years, respectively. Number of overall lesions and the sum of their diameter at the moment of the first RFA significantly affected OS in multivariate analysis. Minor and major complication rates were 14% and 7%, respectively. Conclusion: Tumor size ≥20 mm was associated with lower LTPFS, representing a potential useful threshold value. A careful evaluation of tumor burden appears as a crucial element in choosing the best therapeutic strategy in unresectable ICC.

Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience / Brandi G.; Rizzo A.; Dall'Olio F.G.; Felicani C.; Ercolani G.; Cescon M.; Frega G.; Tavolari S.; Palloni A.; De Lorenzo S.; Abbati F.; Mollica V.; Ricci A.D.; Serra C.. - In: INTERNATIONAL JOURNAL OF HYPERTHERMIA. - ISSN 0265-6736. - STAMPA. - 37:1(2020), pp. 479-485. [10.1080/02656736.2020.1763484]

Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience

Brandi G.;Dall'Olio F. G.;Felicani C.;Ercolani G.;Cescon M.;Frega G.;Tavolari S.;Palloni A.;De Lorenzo S.;Abbati F.;Mollica V.;Ricci A. D.;
2020

Abstract

Background & aims: Very few data are available in literature about the role of radiofrequency ablation (RFA) in intrahepatic cholangiocarcinoma (ICC) and previous studies are mainly case reports and case series on a very small number of patients and nodules. In this study, we aimed to evaluate effectiveness and safety of RFA for the treatment of unresectable ICC. Methods: This is a retrospective observational cohort study comprising all consecutive patients treated with RFA for unresectable ICC at Policlinico Sant’Orsola Malpighi Hospital, Bologna, Italy. Primary endpoint was Local Tumor Progression-Free Survival (LTPFS) while Overall Survival (OS) was also assessed as secondary endpoint. Results: From January 2014 to June 2019, 29 patients with 117 nodules underwent RFA. Technique effectiveness 1 month after RFA was 92.3%; median LTPFS was 9.27 months. Univariate analysis and multivariate analysis showed that LTPFS was significantly related to tumor size ≥20 mm. At a median follow up of 39.9 months, median OS from the date of RFA was 27.5 months, with an OS of 89%, 45% and 11% at 1, 2 and 4 years, respectively. Number of overall lesions and the sum of their diameter at the moment of the first RFA significantly affected OS in multivariate analysis. Minor and major complication rates were 14% and 7%, respectively. Conclusion: Tumor size ≥20 mm was associated with lower LTPFS, representing a potential useful threshold value. A careful evaluation of tumor burden appears as a crucial element in choosing the best therapeutic strategy in unresectable ICC.
2020
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience / Brandi G.; Rizzo A.; Dall'Olio F.G.; Felicani C.; Ercolani G.; Cescon M.; Frega G.; Tavolari S.; Palloni A.; De Lorenzo S.; Abbati F.; Mollica V.; Ricci A.D.; Serra C.. - In: INTERNATIONAL JOURNAL OF HYPERTHERMIA. - ISSN 0265-6736. - STAMPA. - 37:1(2020), pp. 479-485. [10.1080/02656736.2020.1763484]
Brandi G.; Rizzo A.; Dall'Olio F.G.; Felicani C.; Ercolani G.; Cescon M.; Frega G.; Tavolari S.; Palloni A.; De Lorenzo S.; Abbati F.; Mollica V.; Ricci A.D.; Serra C.
File in questo prodotto:
File Dimensione Formato  
Percutaneous radiofrequency ablation in.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.27 MB
Formato Adobe PDF
1.27 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/875703
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 63
  • ???jsp.display-item.citation.isi??? 57
social impact